Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax (NASDAQ:NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company ...

The Novavax Covid-19 vaccine, which goes by the Scrabble-friendly trade name “Nuvaxovid,” has been authorized as a two-dose primary series given three weeks. or roughly only two Scaramuccis apart.

Approval of Novavax vaccine targeting JN.1 variant comes days after mRNA coronavirus vaccines from Pfizer-BioNTech and Moderna hit shelves.

The first results from a large efficacy study of a new kind of COVID-19 vaccine are now out, and they are good. Very good. According to Novavax, the vaccine's manufacturer, it had a 100% efficacy ...

Novavax to become third COVID-19 vaccine available for fall shots. It's based on protein technology, rather than mRNA.

The Novavax vaccine appears to be about 90% effective at preventing mild, moderate and severe COVID-19, Food and Drug Administration scientists say in an analysis of the company's data.

Novavax’s UK trial, with more than 15,000 participants ages 18 to 84, found that the vaccine had an efficacy of 96.4% against mild, moderate and severe disease caused by the original coronavirus ...

In this Feb. 26, 2022 file photo a kidney dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use at a vaccination center in Prisdorf, Germany, Feb. 26, 2022.

The two-shot vaccine was authorized for use in people 18 years and older. Novavax is the fourth COVID-19 vaccine to receive emergency use authorization in the U.S. by the FDA.

A federal advisory committee recommended Tuesday that a fourth COVID-19 vaccine be authorized for use in the USA, this one from Novavax, a company based in Gaithersburg, Maryland.

Novavax is new in the covid-fighting arsenal, but it uses the same technology as more established vaccines. Here's how it differs from Pfizer, Moderna and Johnson & Johnson.